Back to Agenda
Session 1: The Basics: Why We Do What We Do
Session Chair(s)
William Gregory, PhD
Senior Director, Safety and Risk Management
Pfizer Inc, United States
- This session provides longitudinal context for the evolving safety profile in a clinical development program and why continuous safety monitoring and evaluation are important. Three case studies underscore the importance of impeccable attention to drug safety during all phases of clinical development.
Have an account?